InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,660.00
(
0.33%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.15
(
0.23%
)
Bitcoin
62,890.35
(
-0.25%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Maciste

Send PM Follow Ignore
Followers 14
Posts 2555
Boards Moderated 0
Alias Born 07/28/2011

Maciste

Re: None

Friday, 12/23/2016 8:14:50 AM

Friday, December 23, 2016 8:14:50 AM

Post# of 80490
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.



I criticized Ariad Pharmaceuticals (ARIA) for jacking up the price of Iclusig and questioned the sanity of those who believe the lung cancer drug brigatinib is anything more than a me-too late comer. Still, Ariad's share price almost doubled in value in 2016, mainly on takeout speculation. Ouch! My grade: Incomplete (because I still don't believe Ariad will be acquired.)


Apparently he does not believe ARIA will be acquired.

Mr. Denner is time to sell this company.

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up